Avalo Therapeutics Stock: BofA Sees 156% Upside with New Buy Rating
Strong analyst support for abdakibart in hidradenitis suppurativa as Avalo advances to Phase 3.
/ 124 items
#XY Analyst Up/Down↓
5 Hot Biotech Stocks With Fresh Buy Ratings
Analysts initiate coverage with Buy ratings on Sensei (SNSE), Septerna (SEPN), Kazia (KZIA), NervGen (NGEN), and Sutro (STRO).
Casgevy Outlook: Morgan Stanley’s Take on CRISPR Therapeutics
Morgan Stanley upgraded CRISPR Therapeutics to Equal Weight, $60 target (~21% upside), sees Casgevy growth but mixed valuation views.
Chardan Slaps “Buy” Rating on CAMP4 Therapeutics – $6.50 Price Target Signals 60%+ Upside
Its new gene-boosting drug shows promise for rare brain disorders with no treatments yet.
B. Riley Sees Multi-Billion Dollar Potential in Elicio’s mKRAS Vaccine
B. Riley sees Elicio as a strong Buy; mKRAS cancer vaccine data in June could be a major stock catalyst.
Barclays Predicts Oscar Health Will Benefit Most from ACA Boom
Barclays raised Oscar Health rating, sees higher price target as ACA growth and pricing gains boost future profits.